Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10978956 | 0.88 | CA1 (0.46) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL27013074 | 0.85 | CA1 (0.43) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL2760872 | 0.84 | CA1 (0.45) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL13044120 | 0.84 | CA1 (0.45) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL13413134 | 0.84 | CA1 (0.45) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL27013076 | 0.83 | CA1 (0.41) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL2840815 | 0.83 | CA1 (0.44) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL9676521 | 0.82 | CA1 (0.46) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL9675593 | 0.82 | CA1 (0.46) | CA1CA2CA7CTSLCTSB | |
| SCHEMBL13413131 | 0.82 | CA1 (0.45) | CA1CA2CA7CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267609-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | GHOSH ARUN K | 2010-10-21 | — | — | US | disclosed |
| US-7659289-B2 | Hydroxyethylene-based β-secretase inhibitors and use thereof | COMENTIS, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| EP-1448218-A4 | BETA-SECRETASE INHIBITORS AND METHODS OF USE | OKLAHOMA MED RES FOUND (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20080207527-A1 | Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof | COMENTIS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080125467-A1 | Amino-Containing Compounds Which Inhibit Memapsin 2 Beta-Secretase Activity and Methods of Use Thereof | COMENTIS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-7335632-B2 | Beta-secretase inhibitors and methods of use thereof | COMENTIS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20060234944-A1 | Beta-secretase inhibitors and methods of use | OKLAHOMA MEDICAL RESEACH FOUNDATION (US) | 2006-10-19 | — | — | US | disclosed |
| US-20050239684-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | ZAPAQ, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1448218-A2 | BETA-SECRETASE INHIBITORS AND METHODS OF USE | Oklahoma Medical Research Foundation (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040121947-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2003039454-A2 | BETA-SECRETASE INHIBITORS AND METHODS OF USE | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2003-05-15 | — | — | WO | disclosed |
| US-5712417-A | Inhibitors of retroviral proteases | ABBOTT LABORATORIES (US) | 1998-01-27 | — | — | US | disclosed |
| EP-0428849-A2 | Retroviral protease inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267609-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE2, BACE1, PSEN2 | CA1 785/4885CA2 2737/4885CA7 4230/4885 |
| US-20060234944-A1 | Beta-secretase inhibitors and methods of use | BACE2, BACE1, PSEN2 | CA1 736/4885CA2 2329/4885CA7 4229/4885 |
| US-20050239684-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | BACE1, BACE2, APP | CA1 351/4885CA2 3094/4885CA7 3215/4885 |
| US-20080125467-A1 | Amino-Containing Compounds Which Inhibit Memapsin 2 Beta-Secretase Activity and Methods of Use Thereof | BACE2, BACE1, PSEN2 | CA1 640/4885CA2 2419/4885CA7 4280/4885 |
| US-20040121947-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | BACE2, BACE1, PSEN2 | CA1 554/4885CA2 2853/4885CA7 4237/4885 |
| US-20080207527-A1 | Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof | BACE1, BACE2, PSEN1 | CA1 313/4885CA2 2680/4885CA7 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.